- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
-
Profile
- Financials
Ernexa Therapeutics (ERNA)
Company Profile
| Quarter (USD) | Sep 25 | Jun 25 | Mar 25 | Dec 24 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 3.05 mm | 3.05 mm | 3.05 mm | 3.05 mm | 3.05 mm | 3.05 mm |
| Cash burn (monthly) | 422.67 k | 101.42 k | 664.33 k | 1.59 mm | 424.00 k | 784.50 k |
| Cash used (since last report) | 1.90 mm | 455.69 k | 2.98 mm | 7.14 mm | 1.91 mm | 3.52 mm |
| Cash remaining | 1.15 mm | 2.59 mm | 62.00 k | -4.09 mm | 1.14 mm | -477.93 k |
| Runway (months of cash) | 2.7 | 25.6 | 0.1 | -2.6 | 2.7 | -0.6 |
| 13F holders | Current |
|---|---|
| Total holders | 6 |
| Opened positions | 0 |
| Closed positions | 14 |
| Increased positions | 3 |
| Reduced positions | 0 |
| 13F shares | Current |
|---|---|
| Total value | 4.78 mm |
| Total shares | 14.72 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Freebird Partners | 5.14 mm | $2.26 mm |
| Factor Bioscience | 4.22 mm | $0.00 |
| Iaf | 2.68 mm | $1.18 mm |
| Custard & Pitts Investment | 1.40 mm | $0.00 |
| Nicholas Jason Singer | 1.00 mm | $366.00 k |
| Purchase Capital | 280.42 k | $974.00 k |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 21 Jun 25 | Gurrola Sandra M | Common Stock | Option exercise | Acquire M | No | No | 0 | 30 | 0.00 | 110 |
| 21 Jun 25 | Gurrola Sandra M | RSU Common Stock | Option exercise | Acquire M | No | No | 0 | 30 | 0.00 | 0 |
| 9 Jun 25 | Charles Cherington | Common Stock | Buy | Acquire P | No | No | 0.1046 | 21,241,163 | 2.22 mm | 41,659,743 |
| 2 Apr 25 | Charles Cherington | Common Stock | Buy | Acquire P | No | No | 0.1046 | 3,768,397 | 394.17 k | 20,401,602 |
| 7 Feb 25 | William A. Wexler | Stock Option Common Stock | Grant | Acquire A | No | No | 0.34 | 124,533 | 42.34 k | 124,533 |
| 7 Feb 25 | Gurrola Sandra M | Stock Option Common Stock | Grant | Acquire A | No | No | 0.34 | 150,000 | 51.00 k | 150,000 |